Publication: Rat intra-hippocampal NMDA infusion induces cell-specific damage and changes in expression of NMDA and GABAA receptor subunits
Rat intra-hippocampal NMDA infusion induces cell-specific damage and changes in expression of NMDA and GABAA receptor subunits
Date
Date
Date
Citations
Rambousek, L., Kleteckova, L., Kubesova, A., Jirak, D., Vales, K., & Fritschy, J.-M. (2016). Rat intra-hippocampal NMDA infusion induces cell-specific damage and changes in expression of NMDA and GABAA receptor subunits. Neuropharmacology, 105, 594–606. https://doi.org/10.1016/j.neuropharm.2016.02.035
Abstract
Abstract
Abstract
Excessive stimulation of NMDA receptors with glutamate or other potent agonists such as NMDA leads to excitotoxicity and neural injury. In this study, we aimed to provide insight into an animal model of brain excitotoxic damage; single unilateral infusion of NMDA at mild dose into the hippocampal formation. NMDA infusion induced chronic, focal neurodegeneration in the proximity of the injection site. The lesion was accompanied by severe and progressive neuroinflammation and affected preferentially principal neurons while sparing GABAe
Additional indexing
Creators (Authors)
- Rambousek, Lukas
- Kleteckova, Lenka
- Kubesova, Anna
- Jirak, Daniel
- Vales, Karel
- Fritschy, Jean-Marc
Volume
Volume
Volume
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Citations
Rambousek, L., Kleteckova, L., Kubesova, A., Jirak, D., Vales, K., & Fritschy, J.-M. (2016). Rat intra-hippocampal NMDA infusion induces cell-specific damage and changes in expression of NMDA and GABAA receptor subunits. Neuropharmacology, 105, 594–606. https://doi.org/10.1016/j.neuropharm.2016.02.035
